“The performance of NGAL in these and other clinical studies appears sufficient to recommend its inclusion in an early diagnostic panel for AKI, suggesting that we will likely see rapid expansion of its use in the coming years.”

Pumpa (Medicoinvestor Investigator Extraordinaire) found this interesting article:

In a paper from 2 Canandian Docteurs at the  Hópital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, Quebec the status of AKI is reviewed. The development in myocardial infarction and non-development in therapies for AKI are discussed. quote:

When comparing the progress in the diagnosic tools available for AKI to that of myocardial infarction, the state-of-the-art is lagging significantly. Fifty years ago creatinine kinase (CK) was the only available marker for cardiac injury, as was serum creatinine for renal injury. In current practice, cardiac injury is identified through several laboratory tests, such as levels CK-MB, Troponin-I, Troponin-T, Myoglobin, and BNP. However, creatinine is still the only biomarker routinely used to identify kidney injury.

unquote:

the various Biomarkers are discussed- NGAL, Cystatin C,  KIM-1,  IL-18, L-FABP, NGAL emerges as the winner, the others might be good supplements. In short – the canadian doctors do not see NGAL as THE only relevant Biomarker, but certainly the most investigated one… Although they are probably right, there can be specific situations where the other markers equals or outperformes NGAL  – I am convinced that BioPorto via the NGAL Test will get the Lions share of the market – where the other promising markers will be used as additional tests.  When mentioning NGAL – this is the central phrase:

The performance of NGAL in these and other clinical studies appears sufficient to recommend its inclusion in an early diagnostic panel for AKI, suggesting that we will likely see rapid expansion of its use in the coming years.

Please use some time on this yourself:

http://cdn.intechopen.com/pdfs/37096/InTech-Acute_kidney_injury_following_cardiac_surgery_prevention_diagnosis_and_management.pdf

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years :)

 

One Response to Rapid expansion of NGAL test in coming years

  1. […] Rapid expansion of NGAL test in coming years […]

What do you say?

Set your Twitter account name in your settings to use the TwitterBar Section.